Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.

Date publication

juin 2017

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier

Tous les auteurs :
Bröckelmann PJ, Müller H, Casasnovas O, Hutchings M, von Tresckow B, Jürgens M, McCall SJ, Morschhauser F, Fuchs M, Borchmann P, Moskowitz CH, Engert A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28327958

Résumé

Novel agents are changing the treatment of relapsed or refractory Hodgkin lymphoma (HL). Nevertheless, high-dose chemotherapy and autologous stem-cell transplantation (ASCT) are considered standard of care in eligible patients. To identify patients who could benefit most from novel therapeutic approaches, we investigated a comprehensive set of risk factors (RFs) for survival after ASCT.

Mots clés

Adult, Aged, Female, Hematopoietic Stem Cell Transplantation, Hodgkin Disease, therapy, Humans, Male, Middle Aged, Prognosis, Proportional Hazards Models, Recurrence, Risk Factors, Survival Analysis

Référence

Ann. Oncol.. 2017 Jun 1;28(6):1352-1358